High dose niacin can get a person into trouble. It’s prescribed in higher doses (but in delayed release formulations) to treat some forms of hyperlipidemia, but is much less used these days due to potential side-effects and less than stellar efficacy.
Concerns related to adverse effects from uptodate.com:
• Flushing/pruritus: Flushing and pruritus, common adverse effects of niacin, may be attenuated with a gradual increase in dose, administering with food, avoidance of concurrent ingestion of ethanol or hot liquids, and/or by taking aspirin (adults: 325 mg) 30 minutes before dosing (Stone, 2013). May also use other NSAIDs according to the manufacturer. Flushing associated with extended release preparation is significantly reduced (Guyton, 2007). For immediate release preparations, may administer in 2 to 3 divided doses to reduce the frequency and severity. Niacin should not be used if patient experiences persistent severe cutaneous symptoms during therapy (Stone, 2013).
• Gastrointestinal effects: May cause gastrointestinal distress, vomiting, diarrhea, or aggravate peptic ulcer; gastrointestinal distress may be attenuated with a gradual increase in dose and administration with food. Use is contraindicated in patients with active peptic ulcer disease; use with caution in patients with a past history of peptic ulcer. Niacin should not be used if patient experiences unexplained abdominal pain or gastrointestinal symptoms or unexplained weight loss during therapy (Stone, 2013).
• Hematologic effects: Dose-related reductions in platelet count and increases of prothrombin time may occur.
• Hepatotoxicity: Cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred when immediate release (crystalline) niacin products have been substituted with sustained-release (modified release, timed-release) niacin products at equivalent doses. Patients should be initiated with low doses (eg, niacin extended-release 500 mg at bedtime) with titration to achieve desired response. Liver function tests should be monitored in all patients receiving lipid-lowering doses of niacin. Niacin should not be used if hepatic transaminase elevations >2 to 3 times upper limit of normal occur during therapy (Stone, 2013).
• Hypophosphatemia: Has been associated with small but statistically significant dose-related reductions in phosphorus levels. Monitor phosphorus levels periodically in patients at risk for hypophosphatemia.
My advice? Don’t do it. Niacin deficiency in this day and age is almost unheard of.